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Abstract
This retrospective multicenter cohort study investigated the kinetics (ascending and
descending phases) of cytomegalovirus (CMV) and Epstein-Barr virus (EBV)-DNA in whole
blood (WB) and plasma samples collected from adult kidney transplant (KT) recipients.
CMV-DNA kinetics according to antiviral therapy were investigated. Three hundred twenty-
eight paired samples from 42 episodes of CMV infection and 157 paired samples from 26 epi-
sodes of EBV infection were analyzed by a single commercial molecular method approved
by regulatory agencies for both matrices. CMV-DNAemia followed different kinetics in WB
and plasma. In the descending phase of infection, a slower decay of viral load and a higher
percentage of CMV-DNA positive samples were observed in plasma versus WB. In the
72.4% of patients receiving antiviral therapy, monitoring with plasma CMV-DNAemia versus
WB CMV-DNAemia could delay treatment interruption by 7–14 days. Discontinuation of ther-
apy based on WB monitoring did not result in relapsed infection in any patients. Highly differ-
ent EBV-DNA kinetics in WB and plasma were observed due to lower positivity in plasma;
EBV positive samples with a quantitative result in both blood compartments were observed in
only 11.5% of cases. Our results emphasize the potential role of WB as specimen type for
post-KT surveillance of both infections for disease prevention and management.
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Introduction
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) have a central role in kidney transplant
recipients (KTRs) [1]. Specifically, CMV is associated with detrimental direct and indirect
effects (such as chronic allograft nephropathy and/or allograft loss) [2]. EBV has a pivotal role
in the pathogenesis of post-transplant lymphoproliferative disorder (PTLD), a life-threatening
complication [3]. Early detection of viral replication and optimal treatment of active infection
may significantly impact transplant outcomes [2,4]. However, which of the blood compart-
ments–whole blood (WB) or plasma–is optimal for testing is unclear [5]. In solid organ trans-
plant (SOT), kinetics analyses have never been performed of CMV and EBV-DNAemia in WB
and plasma using a single, approved molecular method for quantifying CMV and EBV-DNA
in both blood matrices. In a previous study [6], we investigated the kinetics of both CMV and
EBV-DNAemia in WB and plasma collected from pediatric and adult allogeneic hematopoietic
stem cell transplant (HSCT) recipients using a CE-marked and FDA-approved automated
molecular method. These data demonstrated that CMV and EBV-DNAemia follow different
kinetics in the two blood compartments in HSCT [6]. In the present study, we investigated the
kinetics (ascending and descending phases) of both viruses in WB and plasma samples col-
lected from adult KTRs. These observations may impact monitoring, prophylactic and thera-
peutic management strategies for these infections.
Materials and methods
Study design
In this retrospective non-interventional multicenter cohort study, adult patients who under-
went KT at four Italian transplant centers (Bologna, Pavia, Turin and Cosenza) in the period
between June 2014 and October 2015 were enrolled. At each transplant center, routine virolog-
ical surveillance for CMV and EBV was performed on EDTA-anticoagulated WB samples
using local molecular assay following the same time-schedule. In particular, virological mea-
surements were performed weekly for 3 months after transplant, twice a month from months
3–6, and then monthly from months 6–12. Afterwards, blood samples were analyzed if clini-
cally indicated. Clinical intervention strategies for CMV and EBV infections (Table 1) were
guided by the results obtained. Mode of storage and selection criteria of the samples to investi-
gate, using a single automated quantitative commercial PCR assay (see below), were those pre-
viously reported for allogeneic HSCT recipients [6]. Of note, in the four centers, samples were
consistently handled in terms of collection, transport and storage conditions (i.e. timing and
temperature of storage as well as time elapsed between blood collection and separation of
plasma) in order to minimize the quantification variability due to the pre-analytical phase.
Molecular assays
Extraction and quantification of CMV and EBV-DNA in paired WB and plasma samples were
performed, as previously described [6], using the commercial automated QIAsymphony RGQ
System (QIAGEN, Hamburg, Germany) and the artus1QS-RGQ kits on the Rotor-Gene Q
instrument (QIAGEN), respectively. Using this certified method, results can be reported as
International Unit (IU)/mL, as recommended by the 2018 international consensus guidelines
on the management of CMV in SOT [7]. However, recent studies have shown that some fac-
tors such as the amplicon size and the fragmentation of circulating viral DNA may impact the
commutability of CMV and EBV quantitative standards [8,9].
In our study, aiming to compare the kinetics of CMV and EBV-DNA in two different blood
compartments, we retained to report the results as copies/mL.
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source. This does not alter our adherence to PLOS
ONE policies on sharing data and materials.
Statistical analysis
In order to include in the analyses the positive samples with values below the lower limit of
quantification (LLoQ) of the assay, the data were transformed to approximately half the LLoQ
value: WB <1,000 copies/mL were transformed to 500 copies/mL in both CMV and EBV
assays; plasma<79.4 copies/mL were transformed to 40 copies/mL in CMV and plasma <316
copies/mL to 150 copies/mL for the EBV assay. The imputation of half the LLoQ to the LLoQ
values is a procedure already proposed to manage not quantifiable samples in other settings
(e.g. pharmacokinetic analyses) [10]. All analyses were performed using log10 copies/mL and
for this reason negative samples were assigned an arbitrary value of 1 copy/mL. For each infec-
tion episode and each blood compartment, the week in which the peak viral load was detected
was marked as week 0, and values of viral load in the five preceding and following weeks were
retained for the analysis of kinetics. Viral load distributions in the two blood compartments
were compared by means of Spearman’s correlation. WB peak values and the corresponding
plasma values were compared using Wilcoxon matched-pair test. Viral load kinetics were first
described by estimating the linear slopes of the ascending and descending phases, and testing
each pair of slopes against the null hypothesis of equality using the Wald test. Subsequently, a
repeated-measures ANOVA with infection episodes nested within compartments was per-
formed on ascending and descending phases separately. This method allowed to verify
whether viral load changed over time, taking into account the non-independence of episodes
between compartments. Model-estimated viral loads from week -5 to week +5 for each com-
partment were obtained, as well as contrasts of viral load at adjacent weeks within the same
compartment and of the two compartments at every week.
All these analyses were conducted on the two overall samples of CMV and EBV infections
and subsequently, only for CMV infection, on patient subgroups based on antiviral therapy
treatment, immunosuppressive regimens and underlying disease. The immunosuppressive
Table 1. CMV and EBV prevention strategies according to transplant center.




R+, D+/R- VGCV– 900 mg once
daily– 3 (R+) and 6 (D+/R-) months
post-TX
NO D+/R- and BSX induction: VGCV– 900
mg once daily– 6 months post-TX R+, R-
and ATG induction: VGCV– 900 mg







off viral DNA levels
anti-CMV agenta –dose
and duration
R+, D+/R- > 100,000 copies/mL WB
VGCVb– 900 mg twice daily
R+, D+/R- > 300,000 copies/mL
WB VGCV– 900 mg twice daily or
GCVb i.v.– 5 mg/kg once daily
R+ and BSX induction > 5,000 copies/mL
WB VGCVb– 900 mg twice daily –
R+ > 5,000
copies/mL WB
GCVb i.v.– 5 mg/
Kg once daily
EBV Cut-off viral DNA
levels drug–dose–
duration
R+, R- > 50,000 copies/mL WB or
when a rapid increase of blood viral
load was detected Reduction of the IS
Anti-CD20 monoclonal antibody
rituximabc– 4 administrations at dose
of 375 mg/m2/week
R+, R- > 5,000 copies/mL WB
abdominal ultrasound, chest x-ray,
head and neck x-ray > 100,000
copies/mL WB Reduction of the IS
Anti-CD20 monoclonal antibody
rituximabc – 4 administrations at
dose of 375 mg/m2/week
No patients enrolled No patients
enrolled
D: donor; R: recipient; +: positive; -: negative; VGCV: valganciclovir; GCV: ganciclovir; BSX: basiliximab; ATG: anti-thymocyte immunoglobulin; TX: transplant; WB:
whole blood; i.v.: intravenous; IS: immunosoppressive therapy.
aThe dosages of the antiviral drugs during therapy were renal function adjusted.
bUntil at least two whole blood samples resulted CMV-DNA negative.
cWhen reducing immunosuppression alone is not sufficient to control EBV-DNAemia or when symptoms suggested EBV-related disease.
https://doi.org/10.1371/journal.pone.0238062.t001
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regimens used in the study cohort are reported in S1 Table. Tests were considered significant
for p-values� 0.05. All analyses were performed using Stata v. 15.1.
Ethics
The study was approved by all four transplant centers’ Ethics Committee (i.e. Comitato Etico
Indipendente di Area Vasta Emilia Centro, Comitato di Bioetica di Pavia, Comitato Etico
Interaziendale A.O.U. Città della Salute e della Scienza di Torino—A.O. Ordine Mauriziano—
A.S.L. Città di Torino Comitato Etico and Comitato Etico Regione Calabria Sezione Area
Nord). All patients provided written informed consent.
Results
Study cohort
Sixty-four adult single KTRs met the study selection criteria, for a total of 68 infection episodes
(42 of CMV infection and 26 of EBV infection), as both first and second episode of CMV and
EBV infection were identified for three and one patients, respectively. Clinical and virological
characteristics of the study population are reported in Table 2. In particular, six episodes of
primary CMV infection (6/42 [D+/R-]; 14.3%) and 1 episode of primary EBV infection (1/26
[D?/R-]; 3.8%) were included in the study cohort. CMV-related symptoms were observed in
18 (18/42; 42.9%) active CMV infection episodes. Viral syndrome with: i) leukopenia (i.e. leu-
kocyte count< 4,000 cells/μl, n = 12 [9 D+/R+, 2 D-/R+, 1 D+/R-]; 66.7%), ii) gastrointestinal
symptoms (n = 3 [D+/R+]; 16.7%), iii) fever and malaise (n = 1 [D+/R+]; 5.5%), and tissue-
invasive disease (n = 2 [D+/R+]; 11.1%) were observed. No EBV-related symptoms were
observed. The total number of paired samples investigated for the search of CMV and
EBV-DNA was 328 and 157, respectively; the median number of sequential paired samples
tested per infection episode was 7 (range, 7–11). Due to the low number of second infection
episodes included in the study, viral load kinetics in WB and plasma were analyzed regardless
of the type (first episode versus relapse) of infection. Similarly, the effect of everolimus on viral
kinetics could not be investigated. The study cohort also comprised a small control group to
confirm the 100% assay specificity reported by the manufacturer. Specifically, 15 paired sam-
ples from 3 patients negative for CMV infection and 10 paired samples from 2 patients nega-
tive for EBV infection were retrospectively investigated.
CMV infection
CMV-DNA kinetics in WB and plasma. Among the 328 samples analyzed, 26 (7.9%)
samples showed discordant results between WB and plasma. In detail, 14/26 (53.8%) samples
were positive in WB (11 samples were positive but below the LLoQ of the assay and 3 samples
were positive with a quantitative result) and negative in plasma. The remaining 12 (46.2%)
samples tested negative in WB and positive in plasma (10 were positive but below the LLoQ
and 2 samples were positive with a quantitative result). CMV-DNA levels in WB and plasma
were highly correlated both when including all samples (Spearman’s correlation ρ = 0.922;
p<0.001, Fig 1A) and the samples with a positive quantitative result in both blood compart-
ments (Spearman’s ρ = 0.904; p<0.001, Fig 1B). All paired samples from CMV-negative
patients resulted DNA negative. The distribution of CMV-DNA values with respect to WB
peak time (T0) was similar in the two blood compartments (Fig 2A and 2B). All plasma sam-
ples were CMV-DNA positive at T0 and in 59.5% of cases (25/42 active infection episodes)
CMV-DNA peak levels were reached simultaneously in the two blood compartments; peak
levels in plasma were reached one week before the peak in WB in 2/42 (4.8%) episodes, and
PLOS ONE Kinetics of CMV and EBV DNA in whole blood and plasma
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following the peak in WB in the remaining 15/42 (35.7%) episodes (among them, 11 were at
week +1). However, median WB CMV-DNA peak values (44,538 copies/mL, range, 1,100–
2,862,000) were higher than their corresponding plasma values (4,452 copies/mL, range, 82–
1,017,000) and differed significantly (Wilcoxon matched-pair test: z = 15.48, p<0.001). In
addition, 12/14 samples (85.7%) tested positive in WB and negative in plasma were detected in
the 5 weeks prior to the peak; these samples were from 10 first infection episodes. Concerning
the descending phase, a significant difference between the results obtained in WB and plasma
was observed. Specifically, a higher percentage of negative or low positive (below the LLoQ)
samples was detected in WB than in plasma at week +1 (25.6% vs. 7.7%; p = 0.013), +2 (50%
vs. 23.7%; p = 0.031) and +3 (61.1% vs. 30.5%; p = 0.017).
Table 2. Clinical and virological characteristics of the study cohort with active CMV or EBV infection.
CMV infection EBV infection
No. of patients (Male/Female) 39 (19/20) 25 (20/5)
No. of active infection episodes
First infection episode 37 18
Relapse of infection 5 8
Total 42 26
No. of samples
Whole blood 328 157
Plasma 328 157
Total 656 314
Antiviral/Anti-CD20 monoclonal antibody therapy—No. of active infection episodes
Treated 34a 0
Not treated 8b 26
Clinical course of active infection episodes
Asymptomatic 24 26
Symptomatic 18 0







Underlying disease–No. of patients
Malformative nephropathy 15 4
End stage renal disease 12 9
Proteinuric nephropathy 8 3
Vascular nephropathy 4 9
Immunosuppressive therapy, Induction–Maintenance—No. of active infection episodes
BSX–FK + steroids + MMF 32 15
ATG–FK + steroids + MMF 6 7
ATG–FK + steroids + EVR 2 3
BSX–FK + steroids + EVR 2 1
D: donor; R: recipient; D?: donor not available; +: positive; -: negative; BSX: basiliximab; FK: tacrolimus; MMF:
mycophenolate mofetil; ATG: anti-thymocyte immunoglobulin; EVR: everolimus.
aFirst infection episode (n = 29)/Relapse of infection (n = 5).
bAll first infection episodes.
https://doi.org/10.1371/journal.pone.0238062.t002
PLOS ONE Kinetics of CMV and EBV DNA in whole blood and plasma
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Viral load in the ascending phase was constantly higher in WB than in plasma, producing
similar linear slopes: β = 0.661 for WB and β = 0.681 for plasma (Wald test: χ2 = 0.27,
p = 0.600) (Fig 3). On the contrary, in the descending phase, viral load values in WB progres-
sively approached those of plasma, and as a result, the WB slope (β = -0.660) was steeper than
the plasma slope (β = -0.540) with a significant difference (Wald test: χ2 = 16.01, p<0.001).
The repeated-measures ANOVA conducted on the ascending phase provided a significant
difference between CMV-DNA WB and plasma values (F = 8.69, p = 0.004), a significant mod-
ification of viral load with time (F = 131.07, p<0.001), while the interaction between compart-
ment and time was not significant (F = 0.58, p = 0.647 with Greenhouse-Geisser correction),
indicating that the difference estimated between WB and plasma did not modify with time
(Fig 4). The estimated increase of viral load between adjacent measurements in the same com-
partment was significant in both compartments for each pair of measurements, with the excep-
tion of the -5 week to -4-week increase. Correspondingly, contrasts between compartments at
the same week were significant at all weeks except for week -5, meaning that from week -4 to
week 0 viral load in WB was always higher than in plasma.
In the descending phase, due to the steeper slope of WB, viral load in WB was significantly
higher than in plasma only at week +1 (p = 0.004) and at week +2 (p = 0.043), while from week
Fig 1. Spearman correlation between viral DNA levels evaluated in plasma and WB samples of KTRs. CMV-DNA values, A: all samples (n = 328 paired samples); B:
positive samples with a quantitative result (n = 186 paired samples). EBV-DNA values, C: all samples (n = 157 paired samples); D: positive samples with a quantitative
result (n = 18 paired samples).
https://doi.org/10.1371/journal.pone.0238062.g001
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+3 onwards, estimates of viral load in the two compartments did not differ significantly (Fig
4). This resulted in no overall difference between WB and plasma values in the descending
phase (F = 1.43, p = 0.256), a significant difference of viral load with time (F = 160.82,
p<0.001) and a non-significant interaction between compartment and time (F = 1.61,
p = 0.198 with Greenhouse-Geisser correction), because from week +3 onwards the two slopes
are almost parallel. The decrease of viral load within the same compartment was significant
between each pair of weeks, for both compartments.
Finally, higher levels of CMV-DNA in WB than in plasma in the ascending phase of infec-
tion was also observed in the 12 patients with leukopenia; in particular, a median difference of
0.77 log10 copies/mL (range, 0.17–1.74) between the two blood compartments was observed
(Wilcoxon matched-pair test: z = -4.93, p<0.001).
CMV-DNA kinetics in WB and plasma according to antiviral therapy,
immunosuppressive regimens and underlying disease
According to monitoring in WB, 29 patients received antiviral therapy during the first infec-
tion episode (Table 2). The slopes of ascending viral load were similar in treated and not-
treated patients, with viral load constantly higher in WB; in the descending phase, slopes were
very similar in not-treated patients, i.e. viral load remained constantly higher in WB, while in
treated patients, the slopes very quickly converged because of a steeper decline of viral load in
WB (Wald test: χ2 = 23.90, p =<0.001) (Fig 5). This pattern was confirmed by the repeated-
measures ANOVA (Fig 6) which overall assessed, for the ascending phase significant differ-
ences between compartments (higher viral load in WB, F = 7.54, p = 0.007), between treatment
(higher viral load in treated, F = 46.56, p<0.001), along time (increasing viral load from week
-5 to week 0, f = 77.30, p<0.001) and non-significant interactions of compartment and treat-
ment with time, indicating that the differences found remained constant during all the
Fig 2. Distribution per week of CMV-DNA values in WB and plasma samples with respect to CMV-DNA peak in WB, placed at T0. A: WB samples. B: plasma
samples.
https://doi.org/10.1371/journal.pone.0238062.g002
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ascending phase. Specifically, viral load differed significantly between compartments in treated
from week -4 onwards and in non-treated from week -3 onwards. On the descending phase,
significant differences were confirmed along time (F = 104.54, p<0.001) and between treat-
ment (higher viral load in treated, F = 41.45, p<0.001), while viral load was not different
between compartments (F = 1.93, p = 0.168). The estimated differences in viral load were sig-
nificant between compartments only at time +1 for treated (F = 5.29, p = 0.022) and always
failed to reach significance for non-treated (F = 2.97, p = 0.086 at time +1), probably also
because of their limited sample size.
Notably, if CMV monitoring had been performed in plasma, in the 72.4% of cases (21/29
patients) the treatment interruption would have been delayed 7–14 days due to residual plasma
CMV-DNAemia signals. None of these patients developed relapse of infection during the
post-transplant follow-up period of at least one-year duration. In the remaining 27.6% of the
cases (8/29 patients), CMV-DNA negativity was achieved simultaneously in the two blood
compartments and three relapse episodes were observed within one month after the resolution
of the first infection episode.
Fig 3. Ascending and descending linear slopes of viral load in WB and plasma, all samples.
https://doi.org/10.1371/journal.pone.0238062.g003
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Consistent results were found analyzing the viral load kinetics in subgroups defined by
immunosuppressive regimens (S1 and S2 Figs) or underlying disease (S3 Fig): in each sub-
group, in the ascending phase the slopes of WB and plasma were almost parallel, while in the
descending phase the WB slope was steeper. The slightly different pattern found in patients
with vascular nephropathy is likely due to the limited size of this subgroup.
Fig 4. ANOVA-estimated ascending and descending trajectories of viral load in WB and plasma, all samples.
https://doi.org/10.1371/journal.pone.0238062.g004
Fig 5. Ascending and descending linear slopes of viral load in WB and plasma, for treated with antiviral therapy and not-treated patients.
https://doi.org/10.1371/journal.pone.0238062.g005
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EBV infection
EBV-DNA kinetics in WB and plasma. Among the 157 samples analyzed, 84 (53.5%)
samples showed discordant results in the two blood compartments. In detail, 83 (98.8%) sam-
ples were positive in WB (66 samples were positive with a quantitative result and 17 were posi-
tive but below the LLoQ of the assay) and negative in plasma; one sample (1.2%) resulted
negative in WB and positive but below the LLoQ of the assay in plasma. The correlation
between WB and plasma values was 0.433 (p<0.001) when all samples were evaluated (Fig 1C)
and 0.767 (p<0.001) when only the positive samples with a quantitative result in both the
matrices (Fig 1D) were compared. All paired samples from EBV-negative patients resulted
DNA negative.
The distribution of EBV-DNA values with respect to WB peak time (T0) was dissimilar in
the two blood compartments (Fig 7A and 7B). EBV-DNA peak levels were not reached simul-
taneously in WB and plasma in the majority of cases (18/26 active infection episodes; 69.2%).
At T0, the median EBV-DNA load was equal to 12,285 copies/mL WB (range, 1,222–341,550)
and below the LLoQ of the assay in plasma, i.e. 150 copies/mL (range, 150–27,900), resulting
in a difference of 2.2 log10 copies/mL (p<0.001). In addition, at WB peak time, the 34.6% of
the plasma samples (9/26 active infection episodes) resulted EBV-DNA negative. Finally, tak-
ing into account the median viral DNA levels, plasma samples tested EBV-DNA negative at
most time-points. In the three time-points with a positive median plasma value, a positivity
below the LLoQ was observed (Fig 8).
Discussion
CMV and EBV-DNAemia detection and quantification by molecular assays during post-trans-
plant period is the gold standard method to diagnose infection, guide preemptive strategies
and monitor response to therapy [4,7]. The optimal blood compartment to test and the
Fig 6. ANOVA-estimated ascending and descending trajectories of viral load in WB and plasma, for treated with antiviral therapy and not-treated patients.
https://doi.org/10.1371/journal.pone.0238062.g006
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optimal viral load cut-off to use for initiating and interrupting preemptive therapy is unclear
[4,7]. The present multicenter study analyzed, for the first time, the kinetics of both CMV and
EBV-DNA in WB and plasma samples collected from adult KTRs during entire episodes of
active infection by using a single CE-marked and FDA-approved automated molecular
method. The correlation of virological results between the two blood sample types was also
established. Notably, since a single approved method was used to test WB and plasma paired
samples, the results obtained are not biased by inter-assay quantification variability due to the
different analytical characteristics of the molecular assays (i.e. the limit of detection, the lower
and upper limit of quantification, reproducibility and accuracy) that are known to affect the
results [11]. The inter-operator reproducibility was also minimized since most samples were
investigated in only one center. Finally, pre-analytical characteristics were consistent among
the centers.
Regarding CMV infection, as previously observed in HSCT [6], despite a consistently high
correlation between CMV-DNA levels in WB and plasma, differences in viral load values and
in CMV-DNA kinetics in the two blood compartments were observed. Analyzing multiple
complete infection episodes, although peak viral load was generally reached simultaneously in
the two blood compartments, a higher percentage of CMV-DNA positive samples was
observed in WB than in plasma in the ascending phase of infection. Although a more sensitive
assay allows an earlier diagnosis of active CMV infection [12], no conclusions about the clini-
cal advantage of the greater sensitivity for detection of CMV-DNA in WB than in plasma can
be drawn from this study. With regard to viral load values, CMV-DNA in WB was constantly
higher (about 1 log10) than in plasma since the onset of infection until the peak of viral load,
after which it immediately decreased more rapidly than in plasma. At 3 weeks after the peak,
viral load was similar in the two blood compartments; thus, only at this time the two measures
could be considered equivalent. These findings confirm a more rapid initial decline in viral
Fig 7. Distribution per week of EBV-DNA levels in WB and plasma samples with respect to EBV-DNA peak in WB, placed at T0. A: WB samples. B: plasma
samples.
https://doi.org/10.1371/journal.pone.0238062.g007
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load in WB than in plasma, both in HSCT and SOT setting [6,12]. The CMV-DNA levels
detected in plasma could represent free CMV-DNA released from cells and tissues [6,12]. In
this regard, a recent study by Tong et al. observed that CMV-DNA in the plasma of SOT recip-
ients is almost exclusively free DNA, highly fragmented and not virion associated [13]. As
reported by the authors, their findings have implications for interpretation of dynamic changes
in serial CMV loads [13]. In particular, in our cohort, in those patients who received antiviral
therapy, the less steep trajectory of plasma viral load after the CMV-DNA peak could led to
hypothesize a slower virological response to treatment than what could be inferred by analyz-
ing the WB viral load trajectory. Moreover, if a plasma PCR assay had been used to guide the
duration of the first course of valganciclovir/ganciclovir treatment, the length of antiviral ther-
apy in about 3/4 of our patients would have been 7–14 days longer due to residual plasma
CMV-DNAemia. Notably, since none of these patients developed a relapse of CMV infection
during the follow-up period, the use of a WB PCR assay, avoiding unnecessary prolonged
treatment, represents savings in terms of drug toxicity and cost of treatment. Unlike the early
descending phase of CMV-DNAemia in which overlapping results were obtained [12], Lisboa
et al. reported that CMV-DNA was detected more frequently in WB than in plasma at the end
Fig 8. Median values of EBV-DNA peak in WB, placed at T0.
https://doi.org/10.1371/journal.pone.0238062.g008
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of antiviral therapy. Two different molecular assays were used by the authors and it can be
speculated that among the reasons for the detection of residual WB CMV-DNAemia was a
higher sensitivity of WB PCR assay than the plasma one [12,14,15]. No difference in the
descending phase of infection between the two blood compartments was observed in the
group of patients who did not require antiviral therapy. However, fewer untreated CMV infec-
tion episodes were available for this study.
The analysis of all WB and plasma sample pairs showed a lower correlation between
EBV-DNA levels than CMV-DNA levels in the two blood compartments. EBV-DNAemia was
more frequently quantified in WB than in plasma. Of note, EBV positive samples with a quan-
titative result in both blood compartments were observed only in 1/10 of cases. Furthermore,
in 1/3 of the infection episodes, peak viral loads were detected in WB samples while their
matched plasma samples were negative. Finally, by analyzing multiple complete infection epi-
sodes, in plasma, unlike in WB, it was not possible to observe an ascending phase, a peak and a
descending phase of EBV-DNAemia. Plasma omits the presence of cell-associated virus which
could explain the marked differences between WB and plasma viral loads and kinetics. Consis-
tent with the literature in both HSCT and SOT [6,16–18], these findings showed the advan-
tages of using WB PCR assay rather than plasma to diagnose active EBV infection and track
viral replication in KTRs. Prior studies demonstrated that WB loads and peripheral blood
mononuclear cells loads (considered an indirect measure of EBV-driven B-cell proliferation)
correlate well and that WB is an acceptable alternative to testing peripheral blood mononu-
clear cells for quantifying EBV-DNA loads [16,17]. However, Kanakry and colleagues investi-
gating the clinical significance of detecting EBV-DNA in plasma and in peripheral blood
mononuclear cells of patients with or without EBV-related diseases, observed that plasma
EBV-DNA was a good marker of EBV+ PTLD and performed better than cellular EBV-DNA
as a marker of a broad range of EBV+ diseases [19].
In conclusion, our results suggest use of WB as specimen type for the post-transplant sur-
veillance of both CMV and EBV infections and highlight that only one specimen type should
be used in serial virological monitoring of each patient in order to ensure result comparability.
In the near future, it is advised that clinical trials be carried out in large cohorts prospectively
assessing whether, and to what extent, the different viral load kinetics in WB and plasma, as
demonstrated in this preliminary study, could have implications on clinical intervention strat-
egies; particularly for guiding anti-CMV therapy administration and identifying patients at
higher risk of developing post-transplant EBV-related complications. It is also suggested that
the kinetics of CMV and EBV-DNA in the two blood compartments according to the type of
infection (first versus recurrent episodes of infection) be investigated.
The establishment of testing methods, frequency of testing and viral DNA thresholds for
preemptive therapy management is an additional future challenge to be faced in order to
obtain a standardized diagnostic and therapeutic approach in the transplant setting.
Supporting information
S1 Table. Induction and maintenance immunosuppressive therapy in the study cohort.
(DOCX)
S1 Fig. Ascending and descending linear slopes of viral load in WB and plasma, for
patients who received basiliximab (BSX) or anti-thymocyte immunoglobulin (ATG) as
induction therapy and a triple drug regimen consisting of tacrolimus, mycophenolate
mofetil and steroids as maintenance therapy.
(TIF)
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S2 Fig. ANOVA-estimated ascending and descending trajectories of viral load in WB and
plasma, for patients who received basiliximab (BSX) or anti-thymocyte immunoglobulin
(ATG) as induction therapy and a triple drug regimen consisting of tacrolimus, mycophe-
nolate mofetil and steroids as maintenance therapy.
(TIF)




The authors would like to thank the Linguistic Consultant, Lucy Scioscia, for editing the
English language text. Members of the AMCLI-GLaIT who contributed to the work are Dr.
Pierangelo Clerici (Hospital of Legnano, ASST Ovest Milanese, Legnano, Italy) and Dr. Cris-
tina Giraldi (SS Annunziata Hospital, Cosenza, Italy), President and Secretary of AMCLI,
respectively.
Author Contributions
Conceptualization: Tiziana Lazzarotto, Rossana Cavallo, Fausto Baldanti.
Data curation: Angela Chiereghin, Antonio Piralla, Giulia Piccirilli, Gabriele Turello, Giulia
Campanini, Liliana Gabrielli, Cristina Costa, Francesca Sidoti, Gabriele Bianco, Maria Vit-
toria Mauro, Francesca Greco.
Formal analysis: Dino Gibertoni.
Funding acquisition: Tiziana Lazzarotto, Rossana Cavallo, Fausto Baldanti.
Investigation: Antonio Piralla, Giulia Piccirilli, Gabriele Turello, Giulia Campanini, Liliana
Gabrielli, Cristina Costa, Giorgia Comai, Gaetano La Manna, Luigi Biancone, Teresa Ram-
pino, Marilena Gregorini, Francesca Sidoti, Gabriele Bianco, Maria Vittoria Mauro, Fran-
cesca Greco.
Supervision: Tiziana Lazzarotto, Rossana Cavallo, Fausto Baldanti.
Writing – original draft: Tiziana Lazzarotto, Angela Chiereghin.
Writing – review & editing: Fausto Baldanti.
References
1. Blazquez-Navarro A, Dang-Heine C, Wittenbrink N, Bauer C, Wolk K, Sabat R, et al. BKV, CMV, and
EBV interactions and their effect on graft function one year post-renal transplantation: results from a
large multi-centre study. EBioMedicine 2018; 34: 113–121. https://doi.org/10.1016/j.ebiom.2018.07.
017 PMID: 30072213
2. Kotton CN. CMV: prevention, diagnosis and therapy. Am J Transplant. 2013; 13: 24–40. https://doi.org/
10.1111/ajt.12006 PMID: 23347212
3. Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol. 2005; 16:
1758–1774. https://doi.org/10.1681/ASN.2004121113 PMID: 15829710
4. Green M, Michaels MG. Epstein–Barr virus infection and posttransplant lymphoproliferative disorder.
Am J Transplant. 2013; 13: 41–54. https://doi.org/10.1111/ajt.12004 PMID: 23347213
5. Abbate I, Piralla A, Calvario A, Callegaro A, Giraldi C, Lunghi G, et al. Nation-wide measure of variability
in HCMV, EBV and BKV DNA quantification among centers involved in monitoring transplanted
patients. J Clin Virol. 2016; 82: 76–83. https://doi.org/10.1016/j.jcv.2016.07.001 PMID: 27467016
PLOS ONE Kinetics of CMV and EBV DNA in whole blood and plasma
PLOS ONE | https://doi.org/10.1371/journal.pone.0238062 August 25, 2020 14 / 15
6. Lazzarotto T, Chiereghin A, Piralla A, Piccirilli G, Girello A, Campanini G, et al. Cytomegalovirus and
Epstein-Barr virus DNA kinetics in whole blood and plasma of allogeneic hematopoietic stem cell trans-
plantation recipients. Biol Blood Marrow Transplant. 2018; 24: 1699–1706. https://doi.org/10.1016/j.
bbmt.2018.03.005 PMID: 29545186
7. Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, et al. The third international
consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Trans-
plantation 2018; 102: 900–931. https://doi.org/10.1097/TP.0000000000002191 PMID: 29596116
8. Hayden RT, Tang L, Su Y, Cook L, Gu Z, Jerome KR, et al. Impact of fragmentation on commutability of
Epstein-Barr virus and cytomegalovirus quantitative standards. J Clin Microbiol. 2019; 58: e00888–19.
https://doi.org/10.1128/JCM.00888-19 PMID: 31619529
9. Naegele K, Lautenschlager I, Gosert R, Loginov R, Bir K, Helanterä I, et al. Cytomegalovirus sequence
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